250 related articles for article (PubMed ID: 30066853)
41. Abrogation of signal transducer and activator of transcription 3 reactivation after Src kinase inhibition results in synergistic antitumor effects.
Johnson FM; Saigal B; Tran H; Donato NJ
Clin Cancer Res; 2007 Jul; 13(14):4233-44. PubMed ID: 17634553
[TBL] [Abstract][Full Text] [Related]
42. Eriocalyxin B induces apoptosis in lymphoma cells through multiple cellular signaling pathways.
Zhang YW; Jiang XX; Chen QS; Shi WY; Wang L; Sun HD; Shen ZX; Chen Z; Chen SJ; Zhao WL
Exp Hematol; 2010 Mar; 38(3):191-201. PubMed ID: 20045442
[TBL] [Abstract][Full Text] [Related]
43. C-Type Lectin-Like Receptor 2 Suppresses AKT Signaling and Invasive Activities of Gastric Cancer Cells by Blocking Expression of Phosphoinositide 3-Kinase Subunits.
Wang L; Yin J; Wang X; Shao M; Duan F; Wu W; Peng P; Jin J; Tang Y; Ruan Y; Sun Y; Gu J
Gastroenterology; 2016 May; 150(5):1183-1195.e16. PubMed ID: 26855187
[TBL] [Abstract][Full Text] [Related]
44. Constitutive JAK/STAT signaling is the primary mechanism of resistance to JAKi in TYK2-rearranged acute lymphoblastic leukemia.
Tavakoli Shirazi P; Eadie LN; Page EC; Heatley SL; Bruning JB; White DL
Cancer Lett; 2021 Aug; 512():28-37. PubMed ID: 33971281
[TBL] [Abstract][Full Text] [Related]
45. Peridinin, a carotenoid, inhibits proliferation and survival of HTLV-1-infected T-cell lines.
Ishikawa C; Jomori T; Tanaka J; Senba M; Mori N
Int J Oncol; 2016 Oct; 49(4):1713-21. PubMed ID: 27499015
[TBL] [Abstract][Full Text] [Related]
46. PRT062607 Achieves Complete Inhibition of the Spleen Tyrosine Kinase at Tolerated Exposures Following Oral Dosing in Healthy Volunteers.
Coffey G; Rani A; Betz A; Pak Y; Haberstock-Debic H; Pandey A; Hollenbach S; Gretler DD; Mant T; Jurcevic S; Sinha U
J Clin Pharmacol; 2017 Feb; 57(2):194-210. PubMed ID: 27406873
[TBL] [Abstract][Full Text] [Related]
47. Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy.
Liao C; Hsu J; Kim Y; Hu DQ; Xu D; Zhang J; Pashine A; Menke J; Whittard T; Romero N; Truitt T; Slade M; Lukacs C; Hermann J; Zhou M; Lucas M; Narula S; DeMartino J; Tan SL
Arthritis Res Ther; 2013 Oct; 15(5):R146. PubMed ID: 24286216
[TBL] [Abstract][Full Text] [Related]
48. Inducible nitric oxide synthase mediates DNA double strand breaks in Human T-Cell Leukemia Virus Type 1-induced leukemia/lymphoma.
Baydoun HH; Cherian MA; Green P; Ratner L
Retrovirology; 2015 Aug; 12():71. PubMed ID: 26265053
[TBL] [Abstract][Full Text] [Related]
49. Thymoquinone enhances the anticancer activity of doxorubicin against adult T-cell leukemia in vitro and in vivo through ROS-dependent mechanisms.
Fatfat M; Fakhoury I; Habli Z; Mismar R; Gali-Muhtasib H
Life Sci; 2019 Sep; 232():116628. PubMed ID: 31278946
[TBL] [Abstract][Full Text] [Related]
50. The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKCdelta and proteasome-dependent regulation of Mcl-1 expression.
Baudot AD; Jeandel PY; Mouska X; Maurer U; Tartare-Deckert S; Raynaud SD; Cassuto JP; Ticchioni M; Deckert M
Oncogene; 2009 Sep; 28(37):3261-73. PubMed ID: 19581935
[TBL] [Abstract][Full Text] [Related]
51. Targeting JAK/STAT Signaling Antagonizes Resistance to Oncolytic Reovirus Therapy Driven by Prior Infection with HTLV-1 in Models of T-Cell Lymphoma.
Islam S; Espitia CM; Persky DO; Carew JS; Nawrocki ST
Viruses; 2021 Jul; 13(7):. PubMed ID: 34372612
[TBL] [Abstract][Full Text] [Related]
52. Jak inhibitor induces S phase cell-cycle arrest and augments TRAIL-induced apoptosis in human hepatocellular carcinoma cells.
Fuke H; Shiraki K; Sugimoto K; Tanaka J; Beppu T; Yoneda K; Yamamoto N; Ito K; Masuya M; Takei Y
Biochem Biophys Res Commun; 2007 Nov; 363(3):738-44. PubMed ID: 17904524
[TBL] [Abstract][Full Text] [Related]
53. Pivotal role of dihydroorotate dehydrogenase as a therapeutic target in adult T-cell leukemia.
Ishikawa C; Mori N
Eur J Haematol; 2024 Jul; 113(1):99-109. PubMed ID: 38558052
[TBL] [Abstract][Full Text] [Related]
54. SYK Targeting Represents a Potential Therapeutic Option for Relapsed Resistant Pediatric
Serafin V; Porcù E; Cortese G; Mariotto E; Veltri G; Bresolin S; Basso G; Accordi B
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31817853
[TBL] [Abstract][Full Text] [Related]
55. Enhanced Antitumor Activity of Cetuximab in Combination with the Jak Inhibitor CYT387 against Non-Small-Cell Lung Cancer with Various Genotypes.
Hu Y; Dong XZ; Liu X; Liu P; Chen YB
Mol Pharm; 2016 Feb; 13(2):689-97. PubMed ID: 26685983
[TBL] [Abstract][Full Text] [Related]
56. Targeting SYK kinase-dependent anti-apoptotic resistance pathway in B-lineage acute lymphoblastic leukaemia (ALL) cells with a potent SYK inhibitory pentapeptide mimic.
Uckun FM; Ek RO; Jan ST; Chen CL; Qazi S
Br J Haematol; 2010 May; 149(4):508-17. PubMed ID: 20151979
[TBL] [Abstract][Full Text] [Related]
57. Role of TGM2 in T‑cell lymphoblastic lymphoma via regulation of IL‑6/JAK/STAT3 signalling.
Wang Y; Zheng N; Sun T; Zhao H; Chen Y; Liu C
Mol Med Rep; 2022 Mar; 25(3):. PubMed ID: 35014680
[TBL] [Abstract][Full Text] [Related]
58. Citarinostat and Momelotinib co-target HDAC6 and JAK2/STAT3 in lymphoid malignant cell lines: a potential new therapeutic combination.
Cosenza M; Civallero M; Marcheselli L; Sacchi S; Pozzi S
Apoptosis; 2020 Jun; 25(5-6):370-387. PubMed ID: 32394008
[TBL] [Abstract][Full Text] [Related]
59. Sesquiterpene dimmer (DSF-27) inhibits the release of neuroinflammatory mediators from microglia by targeting spleen tyrosine kinase (Syk) and Janus kinase 2 (Jak2): Two major non-receptor tyrosine signaling proteins involved in inflammatory events.
Zeng KW; Wang S; Dong X; Jiang Y; Jin HW; Tu PF
Toxicol Appl Pharmacol; 2014 Mar; 275(3):244-56. PubMed ID: 24486434
[TBL] [Abstract][Full Text] [Related]
60. Superoxide-Generating Nox5α Is Functionally Required for the Human T-Cell Leukemia Virus Type 1-Induced Cell Transformation Phenotype.
Shigemura T; Shiohara M; Kato M; Furuta S; Kaneda K; Morishita K; Hasegawa H; Fujii M; Gorlach A; Koike K; Kamata T
J Virol; 2015 Sep; 89(17):9080-9. PubMed ID: 26109726
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
